Johnson & Johnson announced the submission of a supplemental Biologics License Application to the U.S. FDA seeking approval of a subcutaneous induction regimen of Tremfya for the treatment of adults with moderately to severely active UC. The filing is supported by data from the Phase 3 ASTRO study of Tremfya SC induction therapy in adults with UC and builds upon the recent U.S. approval of Tremfya in this indication.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Target reports downbeat Q3, Comcast plans cable TV spinoff: Morning Buzz
- Johnson & Johnson, Merck cutting jobs in China, Bloomberg reports
- Protagonist and JNJ say icotrokinra study for PsO meets endpoint
- Johnson & Johnson announces results from ICONIC-LEADa Phase 3 study
- Eli Lilly sues to change hospital drug discount payments, WSJ reports